Boston Scientific Corporation (NYSE: BSX) experienced a sharp decline in its stock price on Wednesday, falling 3.4% after the medical device maker disclosed that a worldwide cyberattack had disrupted its order processing and shipping operations. The incident, which was identified on August 25 and reported the following day, has raised concerns among investors about potential financial and operational repercussions.
The company's shares closed at $48.17, down $1.69 from the previous session, erasing approximately $2.49 billion in market value based on its 1.474 billion diluted shares outstanding. Trading volume surged to 36.56 million shares, 1.73 times the three-month average of 21.11 million, indicating heightened investor attention and uncertainty.
Scope of the Cyberattack
According to a regulatory filing, the cyberattack caused “disruptions and limitations” to systems responsible for processing and shipping customer orders. Boston Scientific has not yet determined whether the incident will have a material impact on its financial results. The company also flagged potential risks including data loss, lawsuits, regulatory investigations, customer interruption, and reputational harm. The filing did not disclose the identity of the attackers or whether sensitive data was accessed.
The operational impact is significant, as order processing and shipping continue to face disruptions with no clear timeline for restoration. This uncertainty has led analysts to reassess the near-term outlook for the company.
Analyst Projections and Revenue Impact
Evercore ISI analyst Vijay Kumar projected that the cyberattack could reduce Boston Scientific's third-quarter revenue growth by 600 to 700 basis points. Based on the company's sales guidance midpoint of $5.27 billion, this translates to a potential revenue hit of approximately $316 million to $369 million. The market's reaction, however, has been more severe, with the $2.49 billion market value loss being 6.8 to 7.9 times the estimated sales impact, reflecting broader concerns about profit margins, customer service, and the recovery timeline.
Kumar drew parallels to a March cyberattack on Stryker Corporation (NYSE: SYK), which also disrupted order processing, manufacturing, and shipping. Stryker's manufacturing operations resumed after about two weeks, with full recovery taking nearly a month. Despite the disruption, Stryker maintained its 2026 guidance, whereas Boston Scientific has yet to issue a similar statement.
Financial Performance and Outlook
Boston Scientific started the third quarter with clear growth targets, projecting sales growth between 3% and 5%, which would imply revenue of $5.22 billion to $5.32 billion. In the second quarter, the company reported a 7.5% increase in sales to $5.44 billion, with cardiovascular products contributing $3.62 billion (two-thirds of total sales) and MedSurg generating $1.82 billion.
The revenue stream is highly dependent on hospitals receiving devices as procedures are scheduled. Delays in shipments could postpone sales even if underlying demand remains steady. Prolonged disruptions could also increase freight, remediation, and customer-support expenses, further pressuring margins.
Market Reaction and Investor Sentiment
Before the announcement, analysts maintained a positive long-term outlook on Boston Scientific. The consensus price target among 31 analysts stood at $62.69, representing a 30.1% upside from Wednesday's closing price. Evercore reiterated its outperform rating with a $55 price target, suggesting that the current selloff may be overdone if the operational impact is contained.
In premarket trading on Thursday, shares were indicated at $48.40, up 0.48% from Wednesday's close, suggesting some stabilization. Investors will be closely monitoring the pace of system restoration ahead of the regular market open at 09:30 EDT.
The cyberattack on Boston Scientific underscores the growing vulnerability of healthcare companies to cyber threats, which can disrupt critical supply chains and erode investor confidence. As the company assesses the full extent of the damage, the market will be watching for updates on system recovery and any potential financial guidance adjustments.
